氟康唑、酮康唑、伊曲康唑和伏立康唑上市后不良反应信号的挖掘与分析 点击下载
论文标题: 氟康唑、酮康唑、伊曲康唑和伏立康唑上市后不良反应信号的挖掘与分析
英文标题:
中文摘要: 目的:挖掘唑类抗真菌药物氟康唑、酮康唑、伊曲康唑和伏立康唑上市后的安全警戒信号,为临床合理用药提供参考。方法:调取美国FDA不良事件报告系统(FAERS)数据库2004年1月1日-2019年3月30日接收的氟康唑、酮康唑、伊曲康唑和伏立康唑药品不良事件(ADE)报告,采用报告比值比(ROR)数据挖掘方法对这4种唑类药物进行不良反应(ADR)信号挖掘,重点分析该类药品说明书安全性信息所涉及的主要ADR。结果:提取FAERS数据库信息得到氟康唑ADE报告27831例、酮康唑ADE报告5712例、伊曲康唑ADE报告5381例、伏立康唑ADE报告11333例。经ROR法检测,上述4种唑类药物在医学检查、血液和淋巴系统疾病、肾脏和泌尿系统疾病、内分泌疾病与肝胆疾病中均出现ADR强信号。其中,氟康唑、伏立康唑肝毒性ADR信号较强(氟康唑ROR=6.51,伏立康唑ROR=14.65);伊曲康唑类库欣综合征(ROR=24.86)和肾上腺抑制(ROR=44.06)ADR检测结果显示为强信号;酮康唑、伊曲康唑在肾上腺皮质功能不全中ADR信号较强(酮康唑ROR=15.64,伊曲康唑ROR=23.26),而酮康唑在皮肤及皮下组织疾病中ADR信号强度(ROR=2.81)明显强于其他药物。此外,氟康唑、伊曲康唑、伏立康唑引起出血性膀胱炎在其说明书中尚未收录(氟康唑ROR=17.73,伊曲康唑ROR=31.43,伏立康唑ROR=17.06);氟康唑引起网状青斑(ROR=10.50)在其说明书中尚未收录。结论:临床医务人员应加强对氟康唑、酮康唑、伊曲康唑和伏立康唑相关主要ADR差异性的认识,在临床使用过程中,对氟康唑、伊曲康唑、伏立康唑引起出血性膀胱炎,氟康唑引起网状青斑等说明书中未提及、但真实世界发生率又较高的ADR,以及伊曲康唑导致的类库欣综合征和肾上腺抑制等虽然说明书中有提及、但检测结果呈异常强信号的ADR应重点关注。
英文摘要: OBJECTIVE:To excavate the safety warning signals induced by azole antifungal agents ,including fluconazole , ketoconazole,itraconazole and voriconazole after marketing ,and to provide references for rational drug use in the clinic. METHODS:Reporting odds ratio (ROR)data mining algorithm was used to investigate signals of adverse drug event (ADE)for fluconazole,ketoconazole,itraconazole and voriconazole from FDA Adverse Event Reporting System (FAERS)during January 1st,2004 to March 30th,2019. ROR data mining method was used to excavate the ADR signals of the drugs ,and main ADR involved in the safety information of azole antifungal agents instructions were analyzed. RESULTS :A total of 27 831,5 712, 5 381 and 11 333 reports were picked out for fluconazole ,ketoconazole,itraconazole and voriconazole ,respectively. All of these drugs had exhibited high-risk signals detection by ROR ,including medical examination ,blood and lymphatic system disorders , renal and urinary disorders ,endocrine diseases ,hepatobiliary disorders. The hepatotoxic-related ADR signals were mainly concentrated in fluconazole and voriconazole (fluconazole ROR =6.51,voriconazole ROR =14.65);ADR detection results of Cushing’s-like syndrome (ROR=24.86) and adrenal suppression (ROR=44.06) by itraconazole showed high-risk signals ; ketoconazole and itraconazole had showed a strong ADR signal in adrenocortical dysfunction (ketoconazole ROR =15.64, itraconazole ROR =23.26),and the signal intensity of ketoconazole (ROR=2.81)in skin and subcutaneous tissue disorders was significantly higher than that of other drugs . In addition ,hemorrhagic cystitis caused by fluconazole,itraconazole and voriconazole were not included in the drug instructions (fluconazole ROR =17.73,itraconazole ROR =31.43,voriconazole ROR =17.06); netted green spot caused by fluconazole (ROR=10.50)were not included in the drug instructions . CONCLUSIONS:Clinical staff should pay more attention to the differences in serious ADR related to fluconazole ,ketoconazole,itraconazole and voriconazole ; particularly some ADRs not mentioned in the drug instructions but have high incidence such as hemorrhagic cystitis caused by fluconazole,itraconazole,voriconazole and netted green spot caused by fluconazole ,as well as ADRs mentioned in the drug instructions but have abnormally high signal ,such as Cushing ’s-like syndrome and adrenal suppression caused by itraconazole .
期刊: 2020年第31卷第09期
作者: 刘海林,袁红梅,王虎,刁俊林,周春巧,丁晓莉,张雪林,董志,王松
英文作者: LIU Hailin,YUAN Hongmei, WANG Hu,DIAO Junlin,ZHOU Chunqiao,DING Xiaoli,ZHANG Xuelin,DONG Zhi,WANG Song
关键字: 氟康唑;酮康唑;伊曲康唑;伏立康唑;不良反应;信号挖掘;报告比值比
KEYWORDS: Fluconazole;Ketoconazole;Itraconazole;Voriconazole;ADR;Signal mining ;Reporting odds ratio
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!